CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Ide-Cel Proves Highly Effective in Relapsed/Refractory Myeloma

May 13th 2021

Nikhil C. Munshi, MD, discusses how idecabtagene vicleucel has potentially marked the beginning of a new chapter for cellular therapy in multiple myeloma.

Adoption of BCMA-Directed CAR T-Cell Therapy Kickstarts A New Era in Multiple Myeloma

May 10th 2021

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

The Future of Cancer Immunotherapy Lies in Combinational Approaches

May 6th 2021

Arsen Osipov, MD, discusses the potential for ongoing research with immunotherapeutic approaches in gastrointestinal malignancies, including CAR T-cell therapy, bispecific T-cell engagers, and vaccines.

Dr. Grunwald on the Established and Potential Utility of Tisagenlecleucel in ALL

May 5th 2021

Michael R. Grunwald, MD, FACP, discusses the established and potential utility of tisagenlecleucel in patients with acute lymphoblastic leukemia.

FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma

May 3rd 2021

Dr. Abramson discusses the significance of the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.

EU Approval Sought for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 30th 2021

A marketing authorization application has been submitted to the European Medicines Agency for the approval of the CAR T-cell therapy ciltacabtagene autoleucel in the treatment of patients with relapsed and/or refractory multiple myeloma.

Sequential CD19-Directed CAR T-Cell Therapy and Allogeneic Transplant Provide Long-Term Responses in Pediatric B-ALL

April 30th 2021

Sequential therapy with CD19.28ζ-directed CAR T cells followed by allogeneic hematopoietic stem cell transplant induced durable disease control in a significant population of children and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL

April 27th 2021

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Integration of Cellular Therapy Jumpstarts Research Efforts in Acute Leukemias

April 27th 2021

Michael Grunwald, MD, discusses the evolving landscape of cellular therapy in acute leukemias and key research efforts and hypotheses aimed at addressing ongoing challenges.

CAR T-Cell Therapy Enters the Arena in Multiple Myeloma With Ongoing Research Ahead

April 15th 2021

Saad Z. Usmani, MD, FACP, discusses the rapidly changing cellular therapy paradigm in relapsed/refractory multiple myeloma.

Rolling Submission to FDA Completed for Cilta-Cel for Relapsed/Refractory Multiple Myeloma

April 6th 2021

The rolling submission of a biologics license application to support the approval of the investigational BCMA-directed CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma has been completed.

FDA Approval Sought for Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell ALL

April 2nd 2021

A supplement biologics license application has been submitted to the FDA for brexucabtagene autoleucel as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Third-Line CAR T-Cell Therapy Improves Outcomes in B-Cell Lymphomas

April 1st 2021

CAR T-cell therapies are now incorporated into National Comprehensive Cancer Network guidelines as a recommended third-line strategy in this setting, with the most recent addition being lisocabtagene maraleucel.

Canadian Collaborative Launches to Provide Infrastructure for Cancer Cell Therapy Research

March 31st 2021

The Canada Foundation for Innovation has awarded C$5,187,685 to the Canadian Cancer Trials Group at Queen’s University in Kingston, Ontario, Canada, to fund the infrastructure for a new research platform to coordinate the development of new cancer cell therapies.

Liso-Cel Approved in Japan for Relapsed/Refractory Large B-Cell Lymphoma

March 29th 2021

Japan’s Ministry of Health, Labour and Welfare has approved lisocabtagene maraleucel, a CAR T-cell therapy designed to target CD19, for the treatment of patients with relapsed or refractory large B-cell lymphoma, as well as relapsed/refractory follicular lymphoma.

FDA Approves Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma

March 27th 2021

The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Liso-Cel Shows Encouraging Clinical Activity, Safety in Relapsed/Refractory MCL

March 19th 2021

M Lia Palomba, MD, discusses the data from the TRANSCEND-NHL-001 trial and projected how lisocabtagene maraleucel could fit into the treatment paradigm for patients with MCL.

New CAR T-Cell Therapy Approvals Diversify Treatment Options in Large B-Cell Lymphoma

March 18th 2021

Matthew Lunning, DO, discusses discussed the findings from pivotal CAR T-cell therapy trials in LBCL, the potential to utilize these agents in the outpatient setting, how off-the-shelf allogeneic products could further transform outcomes, and the importance of shortening brain-to-vein time for this patient population.

Real-World Data Showcase Favorable Outcomes and Less Toxicity With Axi-Cel in Large B-Cell Lymphoma

March 17th 2021

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma

March 15th 2021

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.